-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2014
March 22
NORTHLAND Signs Strategic Cooperation Agreement with Pangen Co., Ltd. (Korea)
April 17
The recombinant human coagulation factor VIII project has received the Notice of Acceptance for New Drug Clinical Trials from the National Medical Products Administration, and is intended for the prophylactic and replacement treatment of hemophilia A.
July 18
The newly built pharmaceutical plant of Beijing Huonland Pharmaceutical Technology Co., Ltd. has been completed.
August 27
Beijing Huonland Pharmaceutical Technology Co., Ltd. has obtained a drug production license.
December 4th
On December 4, 2014, the company was honored with the title of “Top 50 Most Investment-Valuable Enterprises in China—9th Edition” by QYResearch.
December 12
The company won the “Annual Best Performance Award” in the “Hua Xin Award” selection held by First Finance’s New Third Board.
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005